LINCS MCF 10A Common Project: Rolling-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Dataset 1 of 15: End-point cell counts and normalized growth rate inhibition values for all technical replicates of biological replicate 1. - Dataset (ID:20309)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Time Point (hr) | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value | Assay Plate | Assay Well |
|---|---|---|---|---|---|---|---|---|---|---|
| MCF 10A-H2B-mCherry | Dasatinib | 1.7783 | 83.42 | 770.25 | 4606 | 12031 | 0.3828 | 0.5699 | MN20160304_L02 | F13 |
| MCF 10A-H2B-mCherry | Dasatinib | 1.7783 | 83.42 | 770.25 | 5381 | 12031 | 0.4472 | 0.6327 | MN20160304_L02 | L16 |
| MCF 10A-H2B-mCherry | Dasatinib | 1.7783 | 85.64 | 770.25 | 4692 | 12287 | 0.3819 | 0.5718 | MN20160304_L02 | F13 |
| MCF 10A-H2B-mCherry | Dasatinib | 1.7783 | 85.64 | 770.25 | 5528 | 12287 | 0.4499 | 0.6376 | MN20160304_L02 | L16 |
| MCF 10A-H2B-mCherry | Dasatinib | 1.7783 | 87.86 | 770.25 | 4808 | 12543 | 0.3833 | 0.5761 | MN20160304_L02 | F13 |
| MCF 10A-H2B-mCherry | Dasatinib | 1.7783 | 87.86 | 770.25 | 5609 | 12543 | 0.4472 | 0.6376 | MN20160304_L02 | L16 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 3.21 | 770.25 | 834 | 904 | 0.9219 | 0.4088 | MN20160304_L02 | C15 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 3.21 | 770.25 | 727 | 904 | 0.8037 | -0.2205 | MN20160304_L02 | E18 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 5.44 | 770.25 | 950 | 1012 | 0.9380 | 0.7009 | MN20160304_L02 | C15 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 5.44 | 770.25 | 813 | 1012 | 0.8028 | 0.1466 | MN20160304_L02 | E18 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 7.66 | 770.25 | 1029 | 1090 | 0.9440 | 0.7828 | MN20160304_L02 | C15 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 7.66 | 770.25 | 876 | 1090 | 0.8037 | 0.2928 | MN20160304_L02 | E18 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 10.06 | 770.25 | 1119 | 1218 | 0.9183 | 0.7584 | MN20160304_L02 | C15 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 10.06 | 770.25 | 952 | 1218 | 0.7813 | 0.3774 | MN20160304_L02 | E18 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 12.28 | 770.25 | 1213 | 1358 | 0.8931 | 0.7420 | MN20160304_L02 | C15 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 12.28 | 770.25 | 1026 | 1358 | 0.7555 | 0.4196 | MN20160304_L02 | E18 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 14.50 | 770.25 | 1273 | 1497 | 0.8502 | 0.6887 | MN20160304_L02 | C15 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 14.50 | 770.25 | 1081 | 1497 | 0.7220 | 0.4240 | MN20160304_L02 | E18 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 16.73 | 770.25 | 1307 | 1664 | 0.7852 | 0.6091 | MN20160304_L02 | C15 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 16.73 | 770.25 | 1106 | 1664 | 0.6645 | 0.3846 | MN20160304_L02 | E18 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 18.95 | 770.25 | 1329 | 1832 | 0.7252 | 0.5469 | MN20160304_L02 | C15 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 18.95 | 770.25 | 1110 | 1832 | 0.6057 | 0.3394 | MN20160304_L02 | E18 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 21.17 | 770.25 | 1371 | 2008 | 0.6826 | 0.5174 | MN20160304_L02 | C15 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 21.17 | 770.25 | 1121 | 2008 | 0.5582 | 0.3118 | MN20160304_L02 | E18 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 23.39 | 770.25 | 1372 | 2244 | 0.6113 | 0.4538 | MN20160304_L02 | C15 |